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Abstract
Objective The clinical effectiveness of targeted
intraoperative radiotherapy (TARGIT-IORT) has been
confirmed in the randomised TARGIT-A (targeted
intraoperative radiotherapy-alone) trial to be similar
to a several weeks’ course of whole-breast externalbeam radiation therapy (EBRT) in patients with early
breast cancer. This study aims to determine the costeffectiveness of TARGIT-IORT to inform policy decisions
about its wider implementation.
Setting TARGIT-A randomised clinical trial
(ISRCTN34086741) which compared TARGIT with
traditional EBRT and found similar breast cancer control,
particularly when TARGIT was given simultaneously with
lumpectomy.
Methods Cost-utility analysis using decision analytic
modelling by a Markov model. A cost-effectiveness
Markov model was developed using TreeAge Pro V.2015.
The decision analytic model compared two strategies of
radiotherapy for breast cancer in a hypothetical cohort of
patients with early breast cancer based on the published
health state transition probability data from the TARGIT-A
trial. Analysis was performed for UK setting and National
Health Service (NHS) healthcare payer’s perspective using
NHS cost data and treatment outcomes were simulated for
both strategies for a time horizon of 10 years. Model health
state utilities were drawn from the published literature.
Future costs and effects were discounted at the rate of
3.5%. To address uncertainty, one-way and probabilistic
sensitivity analyses were performed.
Main outcome measures Quality-adjusted life-years
(QALYs).
Results In the base case analysis, TARGIT-IORT was a
highly cost-effective strategy yielding health gain at a
lower cost than its comparator EBRT. Discounted TARGITIORT and EBRT costs for the time horizon of 10 years
were £12 455 and £13 280, respectively. TARGIT-IORT
gained 0.18 incremental QALY as the discounted QALYs
gained by TARGIT-IORT were 8.15 and by EBRT were 7.97
showing TARGIT-IORT as a dominant strategy over EBRT.
Model outputs were robust to one-way and probabilistic
sensitivity analyses.
Conclusions TARGIT-IORT is a dominant strategy over
EBRT, being less costly and producing higher QALY gain.

Strengths and limitations of this study
►► This economic analysis extrapolated TARGIT-A

(targeted
intraoperative
radiotherapy-alone)
randomised trial data over a 10-year time horizon.
►► It is the first cost-effectiveness analyis of TARGITIORT using the Markov model and 5-year published
data.
►► Cost associated with radiation treatment toxicity and
the higher environmental and social costs of taking
a several weeks’ course of radiotherapy were not
included in this study; inclusion of such costs would
further improve the cost-effectiveness of TARGITIORT.

Trial registration number ISRCTN34086741; post results

Introduction
Breast cancer is the most common form
of cancer among women in industrialised
countries, accounting for about 30% of all
female cancers and remains the leading
cause of death among women aged 35–55
years.1 2 The recommended treatment for a
large proportion of women with early localised breast cancer consists of a wide excision
of the primary tumour. To be effective in
controlling the disease, this preferred form
of breast-conserving surgery needs to be
followed by postoperative radiotherapy, traditionally delivered in the form of whole-breast
external-beam radiation therapy (EBRT).3
EBRT after lumpectomy for breast cancer
reduces the risk of local recurrence in the
conserved breast. When the reduction in local
recurrence is more than 10% at 5 years, there
is a demonstrable reduction in mortality at
15 years.4 However, the disadvantage is that
EBRT is traditionally given over 3–6 weeks
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as a course of small daily doses of fractionated radiation.
Such a prolonged course is inconvenient for the patients
and also contributes substantially to a long waiting list.
For many women, the journey to the radiotherapy centre
is very arduous5 and many others find it prohibitive and
choose a mastectomy instead. Furthermore, if there is a
significant delay in treatment, the outcome from breast
cancer can be worse.6 Over the past 20 years, diagnostic
and therapeutic medical interventions have evolved
into more patient-focused, less invasive techniques. The
large international multicentre randomised controlled
trial (RCT) of targeted intraoperative radiotherapy-alone (TARGIT-A) that included 3451 patients from
11 countries has confirmed that, in women with early
breast cancer, the technique of targeted intraoperative
radiotherapy (TARGIT-IORT) is safe and as effective.7
TARGIT-IORT and EBRT resulted in similar local recurrence-free survival.8 Furthermore, recent meta-analysis of
various partial breast irradiation versus whole-breast irradiation studies demonstrates a better overall survival due
to a reduction in non-breast cancer mortality.9 10
Provisional recommendations for the use of TARGITIORT with INTRABEAM in the UK National Health
Service (NHS) were issued by the UK National Institute
for Health and Care Excellence (NICE) on 25 July 2014.11
TARGIT-IORT during lumpectomy was included as
a recommended option for suitable women with early
breast cancer in the 2016 Association of Gynecological
Oncology (AGO) guidelines; AGO is an autonomous
community of the German Society of Gynecology and
Obstetrics (DGGG) and the German Cancer Society.12
The Australian Government Medical Services Advisory
Committee recommended TARGIT-IORT for public
funding (Medicare Benefits Schedule) after considering the available evidence in relation to safety, clinical
effectiveness and cost-effectiveness (CE) in May 2015; it
received budgetary approval and eligible patients from
Australia could avail of this treatment from 1 September
2015.13
TARGIT-IORT is being used worldwide in over 300
centres for the treatment of breast cancer. With over 60
centres each in the USA and Germany, centres in the
Middle Eastern countries, Australasia, Far East, South
America, all offering TARGIT-IORT, more than 20 000
patients have been treated. Over 1000 patients treated in
centres from the USA found excellent results with the use
of TARGIT-IORT.14
Unlike regular radiotherapy, TARGIT-IORT is a singledose internal radiation therapy performed during surgery
after removal of the tumour. TARGIT-IORT delivers
radiotherapy directly into the tumour bed. It is administered at the time of lumpectomy, immediately following
cancer removal, during the same anaesthetic, using a
radiation device INTRABEAM, which was developed by
University College London clinical scientists in collaboration with the industry. The radiation is switched on for
25–30 min and is accurately targeted to the tissues that are
at highest risk of local recurrence. The TARGIT-A trial
2

showed how such a single dose of TARGIT-IORT given at
the time of surgery could eliminate the need for wholebreast EBRT in over 80% of suitable patients. This would
avoid numerous hospital visits and minimise radiation
exposure to healthy tissue and organs.
Although it is obvious that the cost of a treatment
consisting of a single dose of radiation is likely to be less
than a 3–6 weeks’ course of radiation, it is only a formal
CE analysis that can objectively determine the exact
difference in cost.
Therefore, this work aims to determine the CE of
TARGIT-IORT in patients with early breast cancer. This
is necessary as such health economic evaluation of the
TARGIT-IORT using INTRABEAM could inform reimbursement policy decisions and its implementation in
usual practice. We assessed the CE of TARGIT-IORT
compared with EBRT for the treatment of early breast
cancer in the UK.

Materials and methods
Model approach
Modelling is a valuable tool in the systematic and transparent synthesis of evidence to support policy decisions.
With a series of numbers and mathematical and statistical
relationships, modelling creates a representation of realworld events.15 To assess the clinical, social and economic
benefits of TARGIT-IORT over the current practice
of whole-breast irradiation, we constructed a decision
analytic model based on outcome probabilities from the
published TARGIT-A trial data (prepathology cohort)
and costs from the INTRABEAM manufacturer and UK
NHS tariffs.7 Utility values for the model health states
were drawn from the published literature.16 A CE Markov
model was developed using TreeAge Pro V.2015 (TreeAge
Software, Williamstown, Massachusetts, USA) to capture
the costs and outcomes of the two breast cancer radiation therapy options, namely: conventional whole-breast
radiation as reference strategy and TARGIT-IORT using
INTRABEAM as new innovative strategy. Model outputs
were represented in terms of life-years, quality-adjusted
life-years (QALYs), cost and CE ratio. The analysis was
conducted from the NHS healthcare payer’s perspective
and to address uncertainty, one-way and probabilistic
sensitivity analyses were performed. A discount rate of
3.5% was applied to the future costs and effects as per the
NICE pharmacoeconomic guidelines.17
Model description
The decision analytic model compared two competing
breast cancer radiation strategies in a hypothetical cohort
of patients with early breast cancer. Treatment outcomes
were simulated for both strategies for a time horizon of
10 years. We used the TARGIT-A trial as an evidence to
inform the model structure and incorporated disease
progression as various model health states.7 Currently,
these clinical effectiveness data published in the Lancet
are the only level 1 randomised evidence available for the
Vaidya A, et al. BMJ Open 2017;7:e014944. doi:10.1136/bmjopen-2016-014944
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Figure 1
therapy.

Markov model structure. EBRT, external-beam radiation therapy; TARGIT-IORT, targeted intraoperative radiation

TARGIT-IORT. The TARGIT-A trial was conducted as a
pragmatic risk-adapted design reflecting a real-world situation.7
Our model uses five distinct health states: disease free;
local recurrence; distant recurrence; death from breast
cancer; and non-breast cancer death (figure 1). The
TARGIT-A trial defines ‘local recurrence’ as recurrence
in the conserved breast. All patients start the model in
the disease-free state and may then either: stay in the
disease-free state; have a distant recurrence; have a local
recurrence; or die from non-breast-cancer(BC) causes.
Patients moving to the distant recurrence health states
may remain there or die of breast cancer death. Model
cycle length was 1 year.
Model parameters
Transition probabilities
The baseline disease progression parameters used in the
model were obtained from the TARGIT-A trial. Since
TARGIT-A is the only available trial for TARGIT-IORT
effectiveness, all the transition probabilities were calculated using these data. Five-year events rates published in
the study were converted to annual rates using MS Excel
natural logarithm (ln) function and then to annual probabilities using exponential function.7
Costs
The costs included in the model are those for initial radiation treatment by EBRT and TARGIT-IORT along with
the costs of being disease free, cost of local and distant
recurrences. The cost of TARGIT-IORT was supplied
by the manufacturer of INTRABEAM device and was
confirmed with experts. Cost of EBRT includes cost to
deliver 15 fractions of radiotherapy on a megavoltage
machine and the cost of preparation for simple radiotherapy. NICE clinical guideline 80 recommends delivery
Vaidya A, et al. BMJ Open 2017;7:e014944. doi:10.1136/bmjopen-2016-014944

of 15 fractions of radiotherapy to complete a course of
treatment.18 As per the experts, these costs are £157 per
fraction of radiotherapy and £737 for the preparation.
Costs of EBRT and cost of disease-free health states were
taken from the NHS Reference Costs 2012–2013 using a
Health Resource Group (HRG) code. HRG coding is an
activity-based payment system of the NHS England and
HRG grouping consists of patient events that have been
judged to consume a similar level of resource. Costs of
recurrences were taken from published literature19 and
were converted to year 2014 costs using Bank of England
cost conversion tool.20 Total costs of recurrences included
diagnostic and treatment costs of recurrences (local/
distant).
Utility
Utility values for various health states in the model were
assigned from the published literature.19 Authors have
reported that a cross-sectional study of 26 representative
UK patients with early breast cancer was used to derive
utilities for various health states in the model. Utilities for
different health states were elicited using standard gamble
method that compared the health states to perfect and
worse health and then worse health against perfect health
and death. The patients in the various health states in the
model were assigned these utility weights to estimate the
number of QALYs gained. The details of model parameter value point estimates, ranges and their sources are
given in table 1.
Model assumptions
a. All patients enter the model in the disease-free state
after initial breast cancer surgery and radiation
therapy. In this state, patients can die of non-breast
cancer causes.
3

4

Model parameters

0.035

 Outcome discount rate

3092
1200
4231
5417

 Costs of EBRT

 Annual cost of being disease free

 Annual cost of local recurrence

 Annual cost of distant recurrence

0.00221
0.00984
0.0096
0.003
0.009
0.00671
0.0055
0.682
0.569
1
0.989
0.911
0.882

 Probability of disease free to local recurrence in EBRT patients

 Probability of disease free to distant recurrence in TARGIT-IORT patients

 Probability of disease free to distant recurrence in EBRT patients

 Probability of disease free to non-breast cancer death in TARGIT-IORT
patients

 Probability of disease free to non-breast cancer death in EBRT patients

 Probability of breast cancer death in TARGIT-IORT patients

 Probability of breast cancer death in EBRT patients

 Probability of distant recurrence to breast cancer death in TARGIT-IORT
patients

 Probability of distant recurrence to breast cancer death in EBRT patients

 Probability of local recurrence to disease free

 Utility value in disease-free patients

 Utility value in local recurrence

 Utility value in distant recurrence

0.661

0.683

0.742

0.426

0.511

0.00412

0.00503

0.00675

0.0025

0.0072

0.00738

0.00166

0.00318

4063

3173

900

2319

1552

Minimum

1

1

1

0.710

0.853

0.00687

0.00838

0.01125

0.00375

0.012

0.0123

0.00276

0.0053

6771

5289

1200

3865

2586

Maximum

Range

Triangular

Triangular

Triangular

Fixed

Triangular

Triangular

Triangular

Triangular

Triangular

Triangular

Triangular

Triangular

Triangular

Triangular

Triangular

Triangular

Triangular

Triangular

Triangular

Fixed

Fixed

Distribution

Mansel et al19

Mansel et al19

Mansel et al19

Expert opinion/model assumption

Calculated

Calculated

Vaidya et al7

Vaidya et al7

Vaidya et al7

Vaidya et al7

Vaidya et al7

Vaidya et al7

Vaidya et al7

Mansel et al19

Mansel et al19

HRG code JA09H, NHS reference costs
2012–201333

HRG code SC29Z, NHS reference costs
2012–201333

Carl Zeiss, UK

Pharmacoeconomic guidelines (NICE)17

Pharmacoeconomic guidelines (NICE)17

Source

*All costs are in 2014 British pound sterling.
EBRT, external-beam radiation therapy; HRG, Health Resource Group; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; TARGIT-IORT, targeted
intraoperative radio therapy.

Utilities

0.00424

 Probability of disease free to local recurrence in TARGIT-IORT patients

Probabilities

2069

 Costs of TARGIT-IORT

Costs*

0.035

Deterministic
value

 Cost discount rate

Discount rates

Name

Table 1
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Figure 2 Incremental cost-effectiveness scatterplot. Each of the 1000 dots represents the result of the Monte Carlo simulation
of cost-effectiveness of TARGIT-IORT over EBRT. So, if the dot is above the WTP threshold, it means that additional cost is
involved in adopting TARGIT-IORT. If it is below the WPT threshold, then there is health gain at lower cost. In this plot, 97.8%
of the dots are below the WTP threshold of zero. EBRT, external-beam radiation therapy; TARGIT-IORT, targeted intraoperative
radiation therapy; WTP, willingness to pay.

b. It is only possible to die from breast cancer while in
the distant recurrence state.
c. All patients from the local recurrence state are back
to the disease-free state after treatment of local
recurrence.
Model analysis
The model assumes that the patient is always in one of a
finite number of states of health referred to as Markov
states. The time horizon of the analysis is divided into
equal increments of time, referred to as Markov cycles,
in this case 1 year. During each cycle, the cohort of
patients is redistributed over the Markov states, thus
theoretically patients may make a transition from one
state to another. Each state is assigned a utility and a
cost. Total costs and utility for TARGIT-IORT versus
EBRT for the model time horizon were calculated
depending upon the distribution of the cohort over
the Markov states and the length of time spent in each
state. Discounted and undiscounted expected life-years
and costs (discount rate 3.5%) for both strategies were
calculated. Based on the discounted expected values,
the incremental cost-effectiveness ratio (ICER) for
TARGIT-IORT was calculated over EBRT.
Model uncertainty
Sensitivity analysis is intended to allow for the examination of the effects of uncertainties on the results of an
economic evaluation. In any economic model, various
inputs, including outcome probabilities and costs, are
required. These typically come from different sources
Vaidya A, et al. BMJ Open 2017;7:e014944. doi:10.1136/bmjopen-2016-014944

and may be associated with uncertainty. In sensitivity
analysis, the values of these inputs are changed (usually
between a reasonable maximum and minimum value),
and the model is rerun. The extent to which the conclusions that the economic evaluation lead to (eg, one
option is more cost-effective than the other) are consistent across a range of sensitivity analyses reflects the
robustness of the findings. To address the uncertainty
about the clinical effects of treatment, one-way sensitivity analysis and probabilistic sensitivity analysis (PSA)
were performed.
In a one-way sensitivity analysis, a single input is varied
between a maximum and minimum value (±25%). In
PSA, each input parameter into the model is assumed
to arise from a probabilistic distribution of values for
that input. For the one-way (deterministic) sensitivity
analysis, the highest and lowest values of each input
parameter were assumed to be 25% above and below
the original estimate for that parameter.
For PSA, second-order Monte Carlo simulation was
performed to test parameter uncertainty (variability
between different samples coming from one population). PSA allows systematic propagation of uncertainty
in all model parameters by assigning distributions to
parameters and using a Monte Carlo simulation technique. All model parameters derived from the literature
or other sources were considered for accuracy, credibility and plausibility at meetings of the expert panel.
In some cases, identifying a suitable distribution for
estimates and describing the uncertainty around these
5
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Table 2 Cost-effectiveness results
Strategy
EBRT
TARGIT-IORT

Cost
13 280
12 455

Incremental cost
Reference strategy
−825

Effectiveness
7.97
8.15

Incremental effect
Reference strategy
0.18

ICER
Dominant

EBRT, external-beam radiation therapy; ICER, incremental cost effectiveness ratio; TARGIT-IORT, targeted intraoperative radiation therapy.

values was problematic. Therefore, in such circumstances, uncertainty was calculated as a potential range
of plausible values of ±25% of the estimate. It was
assumed that the point estimate was the most likely
‘real’ value and therefore, by using the triangular distribution it was ensured that the upper and lower bounds
of variability did not exceed clinical plausibility. This
distribution emphasises the ‘most likely’ value over the
minimum and maximum estimates. A triangular distribution is a continuous probability distribution with a
probability density function shaped like a triangle.
It is defined by three values: the minimum value, the
maximum value and the real (peak) value. The triangular distribution has a definite upper and lower limit
to avoid extreme values.
Results of 1000 Monte Carlo simulations were graphically displayed in the form of CE planes showing the
uncertainty surrounding the CE of TARGIT-IORT and its
subsequent probability of being cost-effective at different
values of willingness to pay (WTP) thresholds was shown
as Monte Carlo CE acceptability chart.

Results
Base case results
In the base case analysis, TARGIT-IORT was a highly
cost-effective strategy yielding health gain at a lower cost
than its comparator EBRT. The difference in the cost
of delivery of TARGIT-IORT versus EBRT was £1023,
favouring TARGIT-IORT. Discounted TARGIT-IORT and
EBRT costs for the time horizon of 10 years were £12 455
and £13 280, respectively. TARGIT-IORT gained 0.18
incremental QALY as the discounted QALYs gained by
TARGIT-IORT were 8.15 and by EBRT were 7.97. TARGITIORT dominated EBRT as it provides an additional QALY
at a lower cost than EBRT (table 2).
Results of sensitivity analyses
One-way sensitivity analyses revealed that the model was
robust to all one-way sensitivity analyses and TARGITIORT remains a dominant strategy over EBRT in all
parameter variations. Probabilistic sensitivity analyses
were conducted to estimate the effect of overall uncertainty in the economic evaluation through repeated

Figure 3 Monte Carlo acceptability. These bar charts show the number of ICER simulation results as seen in figure 2, above
and below the WTP threshold of zero. It shows that there is a 97.8% probability of TARGIT-IORT being cost effective at the WTP
threshold of zero; the corresponding probability for EBRT being cost-effective is 2.2%. EBRT, external-beam radiation therapy;
TARGIT-IORT, targeted intraoperative radiation therapy; WTP, willingness to pay.
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sampling of mean parameter values from a series of
assigned distribution. In the PSA, the results were robust
over a range of plausible estimates of model parameters.
PSA results are presented as means of 1000 probabilistic
model outputs and were found to be similar to the deterministic results. Based on probabilistic model runs, net
monetary benefit framework was applied to draw the
‘incremental cost-effectiveness’ plane (figure 2) which
shows that TARGIT-IORT is cost saving in 97.8% iterations (figure 3). The CE acceptability chart shows that
TARGIT-IORT is cost-effective at zero thresholds of WTP.
Discussion
We used published data from the TARGIT-A trial to investigate the CE of TARGIT-IORT in patients with early breast
cancer. The findings suggest that in comparison to the
EBRT which involves delivering whole-breast radiations
in multiple sessions, individuals treated with TARGITIORT, during the surgery performed to remove the breast
cancer, had higher mean health gain (QALYs) at a lower
mean cost. The model outputs indicate definite cost
savings by the use of TARGIT-IORT within a risk-adapted
strategy rather than using EBRT in call cases. The model
runs for 10 years which is very conservative as most events
related to breast cancer occur in the first 5 years.21 These
findings, based on extrapolation of the relevant outcomes
obtained from the analysis of complete trial data, were
generally found to be robust to uncertainty surrounding
various model parameter inputs and assumptions. Based
on probabilistic analysis, TARGIT-IORT had a 98%
chance of being cost-effective at zero WTP. The one-way
sensitivity analysis demonstrates that our estimates of the
ICERs were reasonably robust to a 25% change in the
base case input values.
The finding that TARGIT-IORT has the highest chance
of being the most cost-effective option is driven by a
number of factors: (1) its greater estimated QALY and
utility gains due to fewer non-breast-cancer deaths in the
TARGIT-IORT cohort; (2) its lower cost compared with
EBRT; (3) its non-inferiority to EBRT in terms of cancer
recurrence; and (4) the high likelihood of its being superior to EBRT in terms of non-breast-cancer mortality. The
latter is supported by a recently published meta-analysis
of partial breast irradiation versus whole-breast irradiation10 and a published correspondence9 which include
the data from the earliest cohort in the TARGIT-A trial,
which have a median follow-up of 5 years.
This study provides evidence that TARGIT-IORT is
an economically attractive intervention in the carefully
selected eligible patients of early breast cancer. Our
research has been conducted using recognised economic
modelling techniques and followed comprehensive International Society for Pharmacoeconomics and Outcomes
Research - Society for Medical Decision Making (ISPORSMDM) task force guidelines on modelling good research
practices.22 We undertook a wide range of sensitivity analyses and confirmed the robustness of our findings.
Vaidya A, et al. BMJ Open 2017;7:e014944. doi:10.1136/bmjopen-2016-014944

In our model, costs associated with management of
acute and long-term radiotoxicity were not included
because of similar overall toxicity rates in the two treatments (seroma needing aspiration was more common
with TARGIT-IORT 2.1% vs 0.8%, while grade 3 or grade
4 radiation toxicity was more common with EBRT 0.5%
vs 2%). The low level of radiotoxicity (<3%) is unlikely to
make a significant cost difference.
The environmental and social costs5 as well as travel
costs have not been included into the model. These
are usually borne by the patient, but in many health
systems they are borne by the health system. In any case,
these costs including management of toxicity costs will
further add to the CE of TARGIT-IORT.
We would like to believe that the results of this CE analysis may be generalisable in many statutory healthcare
systems. Our belief regarding the generalisability of results
to other similar healthcare systems is based on the fact
that EBRT has relatively high costs than TARGIT-IORT
across the healthcare jurisdictions. TARGIT-IORT costs
will remain lower than EBRT in most healthcare settings
because of many factors even if tariffs are different; EBRT
has a high and recurring investment for the linear accelerators and bunkers, associated with need of maintenance
and personnel attendance; it is labour intensive, which
is deemed to translate into high personnel costs. Moreover, EBRT is delivered in multiple fractions and patient
transportation and accommodation costs can be additionally taken into account. Higher EBRT tariffs from
other healthcare settings and inclusion of cost of EBRT
bunker in this analysis will make ICER more favourable to
TARGIT-IORT.
Complex medical practice is difficult to transform into a
decision model. This study shares the general limitations of
economic modelling along with several other limitations.
Due to data limitations, this analysis used a cohort-based
model ignoring heterogeneity. The time horizon of the
CE analysis was not lifetime but 10 years. Extrapolation
beyond 10 years was not undertaken because of the relatively shorter follow-up period of effectiveness trial. The
analysis was done from payer’s perspective. A societal
perspective could measure costs, including impacts on the
rest of society, patients and families. One weakness of the
study is that the clinical effectiveness data used to inform
disease progression in the model are drawn from a single
albeit large randomised study . Another important limitation was regarding the health state utility weights used in
the economic model. Although these utilities were taken
from UK studies using the EQ-5D and valued using the UK
general population tariff, a small sample size challenges the
validity of these utility weights.
Our CE model results are in line with the previously
published studies from Esserman et al,23 Alvarado et al,24
Picot et al,25 Shah et al26 and Vaidya et al,27 which came to
the same conclusion that TARGIT-IORT is more cost-effective than standard EBRT. Newer EBRT techniques such
as Intensity Modulated Radiotherapy (IMRT) with higher
equipment and human resource costs the difference
7
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between TARGIT-IORT tariffs and EBRT tariffs, even if used
for partial breast irradiation, would have been even higher.
In our CE model, TARGIT-IORT dominates EBRT. Flipping it on its head, if TARGIT-IORT were the standard
strategy, there would be no health-economic justification
for adopting whole breast-EBRT. If no radiation at all is
implemented for very low-risk patients then no radiation
dominates TARGIT-IORT, at the cost of higher local recurrence rate that may not be acceptable to clinicians and
patients. The recurrence rate with no radiotherapy even in
the best prognosis and older patients is up to 1 in 17. With
TARGIT-IORT with just one selection criterion (oestrogen
receptor positive) this is very low (1 in 71).
Preferences elicited from health professionals working
with patients with breast cancer accepted TARGIT-IORT
as an alternative treatment option to EBRT for early breast
cancer.28 In this era where decisions are shared by doctors
and patients, informed by the best evidence available,
reflect patients’ own values and preferences and involve
them more directly, TARGIT-IORT has been shown to be
the preferred choice compared with EBRT by the patients
as well as the doctors.29-32
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